Andreas Wollenberg

28.4k total citations · 9 hit papers
320 papers, 12.0k citations indexed

About

Andreas Wollenberg is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Andreas Wollenberg has authored 320 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Dermatology, 155 papers in Immunology and Allergy and 65 papers in Physiology. Recurrent topics in Andreas Wollenberg's work include Dermatology and Skin Diseases (218 papers), Allergic Rhinitis and Sensitization (122 papers) and Food Allergy and Anaphylaxis Research (66 papers). Andreas Wollenberg is often cited by papers focused on Dermatology and Skin Diseases (218 papers), Allergic Rhinitis and Sensitization (122 papers) and Food Allergy and Anaphylaxis Research (66 papers). Andreas Wollenberg collaborates with scholars based in Germany, United States and Denmark. Andreas Wollenberg's co-authors include Thomas Bieber, Daniel Hanau, Johannes Ring, Thomas Ruzicka, Thomas Werfel, Mette Deleuran, Jonathan I. Silverberg, T Bieber, Stefanie Wetzel and Stefan Kraft and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Andreas Wollenberg

302 papers receiving 11.6k citations

Hit Papers

Consensus‐based European guidelines for treatment of atop... 2016 2026 2019 2022 2018 2016 2017 2020 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
    2018 804 citations Andreas Wollenberg, S. Barbarot et al. Journal of the European Academy of Dermatology and Venereology profile →
  2. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
    2016 440 citations Thomas Werfel, Kilian Eyerich et al. profile →
  3. Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
    2017 414 citations Thomas Ruzicka, Andreas Wollenberg et al. profile →
  4. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    2020 313 citations Eric L. Simpson, Andreas Wollenberg et al. profile →
  5. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
    2018 300 citations Andreas Wollenberg, Jonathan I. Silverberg et al. profile →
  6. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients
    2016 278 citations Andreas Wollenberg, Mette Deleuran et al. Journal of the European Academy of Dermatology and Venereology profile →
  7. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
    2020 173 citations Thomas Bieber, L. Misery et al. profile →
  8. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
    2023 80 citations Amy S. Paller, Carsten Flohr et al. profile →
  9. OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
    2024 39 citations Kenji Kabashima, Richard B. Warren et al. American Journal of Clinical Dermatology profile →

Peers

Andreas Wollenberg
Comparison fields: 5 of 148
  • Dermatology 8.5k
  • Immunology and Allergy 6.1k
  • Physiology 2.8k
  • Immunology 2.5k
  • Rheumatology 1.7k
Replace Lawrence F. Eichenfield with:
Lawrence F. Eichenfield United States
Thomas Werfel Germany
Stephan Weidinger Germany
Alan D. Irvine Ireland
Mark Boguniewicz United States
Peter Schmid‐Grendelmeier Switzerland
Natalija Novak Germany
Kristian Thestrup‐Pedersen Denmark
Eric L. Simpson United States
Kilian Eyerich Germany
Lawrence F. Eichenfield United States View profile →
Citations per field, relative to Andreas Wollenberg
Andreas Wollenberg · 1×
Citations per year, relative to Andreas Wollenberg
Andreas Wollenberg · 1×

Countries citing papers authored by Andreas Wollenberg

Since Specialization
Citations

This map shows the geographic impact of Andreas Wollenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Wollenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Wollenberg more than expected).

Fields of papers citing papers by Andreas Wollenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Wollenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Wollenberg. The network helps show where Andreas Wollenberg may publish in the future.

Co-authorship network of co-authors of Andreas Wollenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Wollenberg. A scholar is included among the top collaborators of Andreas Wollenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Wollenberg. Andreas Wollenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis
2025 ·American Journal of Clinical Dermatology ·Amalie Thorsti Møller Rønnstad, (unknown), Christopher G. Bunick, Raj Chovatiya, (unknown), Farzad Alinaghi, Simon Francis Thomsen, Christian Apfelbacher, Andreas Wollenberg, Alexander Egeberg, Jacob P. Thyssen, Nikolai Loft
0
2
The Burden of Pediatric Atopic Dermatitis: Quality of Life of Patients and Their Families
2024 ·Journal of Clinical Medicine ·(unknown), (unknown), Odilija Rudzevičienė, Matilda Bylaitė-Bučinskienė, Andreas Wollenberg
3
3
Skin Barrier Function Assessment: Electrical Impedance Spectroscopy Is Less Influenced by Daily Routine Activities Than Transepidermal Water Loss
2024 ·Annals of Dermatology ·(unknown), (unknown), Andreas Wollenberg, Jan Gutermuth, Inge Kortekaas Krohn
6
4
NOD/Scid IL2Rγnull Mice Reconstituted with PBMCs from Patients with Atopic Dermatitis or Psoriasis Vulgaris Reflect the Respective Phenotype
2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Franziska Ruëff, Andreas Wollenberg, Matthias Siebeck, Roswitha Gropp
1
5
Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials
2024 ·SKIN The Journal of Cutaneous Medicine ·Kristian Reich, Richard G. Langley, (unknown), D. Staumont‐Sallé, Antonio Costanzo, Andrew Pink, Amy S. Paller, Norito Katoh, Andreas Wollenberg, Richard B. Warren, (unknown), (unknown), Le Gjerum, Eric L. Simpson
2
6
Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review
2023 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Sophie Connétable, Delphine Kérob, (unknown), Luc Aguilar, Andreas Wollenberg
37
7
46 Skin barrier function assessment: electrical impedance spectroscopy is less influenced by daily routine activities than transepidermal water loss
2023 ·Journal of Investigative Dermatology ·(unknown), (unknown), Andreas Wollenberg, Jan Gutermuth, Inge Kortekaas Krohn
0
8
Atopic dermatitis: A global health perspective
2023 ·Journal of the European Academy of Dermatology and Venereology ·Ousmane Faye, Carsten Flohr, Kenji Kabashima, Lin Ma, Amy S. Paller, (unknown), Martin Steinhoff, John Su, Roberto Takaoka, Andreas Wollenberg, Yik Weng Yew, José A Ruiz-Postigo, Peter Schmid‐Grendelmeier, Alain Taı̈eb
30
9
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
2023 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Andrew Pink, Andrew Blauvelt, Melinda Gooderham, April W. Armstrong, Margitta Worm, Norito Katoh, Ketty Peris, L. Puig, S. Barbarot, (unknown), Louise Abildgaard Steffensen, (unknown), Andreas Wollenberg
15
10
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis
2023 ·Journal of the European Academy of Dermatology and Venereology ·Andreas Wollenberg, Jacob P. Thyssen, Thomas Bieber, (unknown), Urs Kerkmann
8
11
Efficacy and Microbiota Modulation Induced by LimpiAL 2.5%, a New Medical Device for the Inverse Psoriasis Treatment
2023 ·International Journal of Molecular Sciences ·Laura Pietrangelo, Annunziata Dattola, (unknown), Giulio Petronio Petronio, (unknown), (unknown), (unknown), Andreas Wollenberg, Giovanni Pellacani, Roberto Di Marco
3
12
Tolérance et efficacité à long terme du tralokinumab chez des adolescents atteints de dermatite atopique modérée à sévère : analyse intermédiaire d’ECZTEND
2023 ·A. Khemis, Eric L. Simpson, Andreas Wollenberg, Anthony Bewley, Michael J. Cork, (unknown), Weily Soong, Peter Almgren, Le Gjerum, (unknown), Amy S. Paller, (unknown)
0
13
How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Andreas Wollenberg, Magdalena Trzeciak
9
14
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores
2023 ·Journal of the European Academy of Dermatology and Venereology ·Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, Ignasi Figueras‐Nart, L. Misery, (unknown), (unknown), Na Lu, Susanne Grond, Kilian Eyerich
6
15
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3
2022 ·British Journal of Dermatology ·Kristian Reich, Eric L. Simpson, Andreas Wollenberg, Robert Bissonnette, Masatoshi Abe, Tracy Cardillo, Jonathan Janes, Luna Sun, (unknown), Jonathan I. Silverberg
11
16
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
2022 ·Acta Dermato Venereologica ·Andreas Wollenberg, Danielle Marcoux, Jonathan I. Silverberg, Valéria Aoki, Eulàlia Baselga, Haixin Zhang, Noah A. Levit, Alain Taı̈eb, Ana B. Rossi
8
17
2020 European guideline on the management of genital molluscum contagiosum
2020 ·Journal of the European Academy of Dermatology and Venereology ·Sarah Edwards, (unknown), M. Janier, Piergiacomo Calzavara‐Pinton, (unknown), (unknown), Franco Rongioletti, Andreas Wollenberg, (unknown), M. Skerlev, (unknown)
19
18
The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group
2019 ·British Journal of Dermatology ·Helen Alexander, Amy S. Paller, Claudia Traidl‐Hoffmann, Lisa A. Beck, Anna De Benedetto, Sandipan Dhar, Giampiero Girolomoni, Alan D. Irvine, Phyllis I. Spuls, John Su, Jacob P. Thyssen, Christian Vestergaard, Thomas Werfel, Andreas Wollenberg, Mette Deleuran, Carsten Flohr
123
19
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
2019 ·British Journal of Dermatology ·Andreas Wollenberg, Lisa A. Beck, Andrew Blauvelt, Eric L. Simpson, Z. Chen, (unknown), Brad Shumel, Faisal A. Khokhar, Thomas Hultsch, E. Rizova, Ana B. Rossi, Neil M.H. Graham, Gianluca Pirozzi, Yuan Lü, Marius Ardeleanu
91
20
Tazarotene 0.015% Cream as a Potential Topical Agent for Management of Ichthyosis in Dorfman-Chanarin Syndrome
2018 ·Acta Dermato Venereologica ·Liviu Niculescu, Cristel Ruini, Jerome Srour, (unknown), Ines Schönbuchner, Tanja von Braunmühl, Thomas Ruzicka, (unknown), Kathrin Giehl, Judith Fischer, Andreas Wollenberg
4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lawrence F. Eichenfield Breakdown of academic impact, for papers by Thomas Werfel Breakdown of academic impact, for papers by Stephan Weidinger Breakdown of academic impact, for papers by Alan D. Irvine Breakdown of academic impact, for papers by Mark Boguniewicz Breakdown of academic impact, for papers by Peter Schmid‐Grendelmeier Breakdown of academic impact, for papers by Natalija Novak Breakdown of academic impact, for papers by Kristian Thestrup‐Pedersen Breakdown of academic impact, for papers by Eric L. Simpson Breakdown of academic impact, for papers by Kilian Eyerich
Rankless by CCL
2026